Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-19
- Development stage
- Unknown
- Lead developer
- WPP
- Administration
- Oral
01
Overview
CH-19 is a homeopathic remedy developed and marketed by Curanter Homeo, a retail company based in Patna, India. The product is available in oral forms, including drops and tablets. It is part of a commercial line of homeopathic products (ranging from CH-19 to CH-31) sold directly to consumers via e-commerce. As a homeopathic preparation, there is no established pharmacological mechanism of action, identified biological targets, or clinical trial data associated with the product. It is classified as a finished retail product rather than a therapeutic candidate in conventional pharmaceutical development.
- Brand names
- CH-19CH19CH 19
- Other names
- CH-19 dropsCH19 dropsCH 19 dropsCH-19 tabletsCH19 tabletsCH 19 tablets
Beyond the preview
Go deeper on CH-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-19.